Opterion Health AG has now closed a financing round that was oversubscribed by 60 percent. According to a press release, the company managed to successfully secure investment totaling 6.5 million Swiss francs. As part of the financing round, additional option capital in the amount of 7.3 million Swiss francs was also issued. Both existing and new private and institutional investors participated in the financing round.
Opterion Health is developing a solution for an innovative peritoneal dialysis (PD) solution. According to information from the company itself, the solution is set to “revolutionize” the dialysis market by replacing the gold standard of the current market leader. At present, the solution is still in the preclinical phase. However, the fresh capital should now help to accelerate the process so that a Phase I clinical trial can begin sooner than originally expected.
In addition to closing the financing round, Opterion Health has also announced a change in personnel. In this context, Stefan Wohlfeil has resigned his seat on the Board of Directors in order to enter retirement. Shareholders have now elected Jan-Anders Karlsson and Robert Leitz as new members of the Board of Directors. The two newcomers will bring many years of experience in the areas of life sciences and finance to the company.
In 2021, Opterion Health moved its headquarters to Muttenz in the canton of Basel-Landschaft, with the aim of exploiting the region’s life sciences ecosystem. In so doing, the company was supported by the investment and innovation promotion agency Basel Area Business & Innovation.